Different downstream signalling of CCK1 receptors regulates distinct functions of CCK in pancreatic beta cells

British Journal of Pharmacology

Volumn 172, Issue 21, 2015, Pages 5050-5067

  Ning, Shang Lei ^a,b,d   Zheng, Wen Shuai ^c,d   Su, Jing ^c,d   Liang, Nan ^a,d   Li, Hui ^c,d   Zhang, Dao Lai ^a,c   Liu, Chun Hua ^c,d   Dong, Jun Hong ^a,d   Zhang, Zheng Kui ^d   Cui, Min ^d   Hu, Qiao Xia ^a,d   Chen, Chao Chao ^c,d   Liu, Chang Hong ^e   Wang, Chuan ^f   Pang, Qi ^e   Chen, Yu Xin ^b   Yu, Xiao ^a,b,c,d   Sun, Jin Peng ^a,c,d,e  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b SHANDONG UNIVERSITY   (China)

^c Shandong Provincial School Key Laboratory for Protein Science of Chronic Degenerative Diseases   (China)

^d SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e SHANDONG UNIVERSITY   (China)

^f HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 1; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CYCLIC AMP; GLUCOSE; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL TRISPHOSPHATE; PROTEIN BCL 2; S6 KINASE; SMALL INTERFERING RNA; ARRB1 PROTEIN, MOUSE; BETA ARRESTIN; CHOLECYSTOKININ RECEPTOR; INSULIN; RETINA S ANTIGEN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL PROTECTION; COMPLEX FORMATION; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE TOLERANCE TEST; INSULIN RELEASE; KNOCKOUT MOUSE; MOUSE; MULTICENTER STUDY; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; CYTOLOGY; GENETICS; METABOLISM; PANCREAS ISLET; PHOSPHORYLATION; PHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; APOPTOSIS; ARRESTINS; BETA-ARRESTIN 1; BETA-ARRESTINS; CHOLECYSTOKININ; INSULIN; ISLETS OF LANGERHANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; RECEPTORS, CHOLECYSTOKININ; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION;

EID: 84945967336     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13271     Document Type: Article

References (70)

1. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ, (2004). Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 279: 35518-35525.
2. Ahren B, (2009). Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 8: 369-385.
3. Ahren B, Holst JJ, Efendic S, (2000). Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab 85: 1043-1048.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
6. Anjum R, Blenis J, (2008). The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9: 747-758.
7. Baggio LL, Drucker DJ, (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157.
8. Broca C, Quoyer J, Costes S, Linck N, Varrault A, Deffayet PM, et al., (2009). beta-Arrestin 1 is required for PAC1 receptor-mediated potentiation of long-lasting ERK1/2 activation by glucose in pancreatic beta-cells. J Biol Chem 284: 4332-4342.
9. Brown LM, Rogers KE, McCammon JA, Insel PA, (2014). Identification and validation of modulators of exchange protein activated by cAMP (Epac) activity: structure-function implications for Epac activation and inhibition. J Biol Chem 289: 8217-8230.
10. Cantor P, (1989). Cholecystokinin in plasma. Digestion 42: 181-201.
11. Cantor P, Rehfeld JF, (1989). Cholecystokinin in pig plasma: release of components devoid of a bioactive COOH-terminus. Am J Physiol 256 (1 Pt 1): G53-61.
12. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL, (2005). Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 (Suppl 2): S97-107.
13. Coffa S, Breitman M, Hanson SM, Callaway K, Kook S, Dalby KN, et al., (2011a). The effect of arrestin conformation on the recruitment of c-Raf1, MEK1, and ERK1/2 activation. PLoS One 6: e28723.
14. Coffa S, Breitman M, Spiller BW, Gurevich VV, (2011b). A single mutation in arrestin-2 prevents ERK1/2 activation by reducing c-Raf1 binding. Biochemistry 50: 6951-6958.
15. Danial NN, Walensky LD, Zhang CY, Choi CS, Fisher JK, Molina AJ, et al., (2008). Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med 14: 144-153.
16. Dong JH, Chen X, Cui M, Yu X, Pang Q, Sun JP, (2012). beta2-adrenergic receptor and astrocyte glucose metabolism. J Mol Neurosci: MN 48: 456-463.
17. Dostmann WR, (1995). (RP)-cAMPS inhibits the cAMP-dependent protein kinase by blocking the cAMP-induced conformational transition. FEBS Lett 375: 231-234.
18. Dou HQ, Xu YF, Sun JP, Shang S, Guo S, Zheng LH, et al., (2012). Thiopental-induced insulin secretion via activation of IP3-sensitive calcium stores in rat pancreatic beta cells. Am J Physiol Cell Physiol 302: C796-C803.
19. Dufresne M, Seva C, Fourmy D, (2006). Cholecystokinin and gastrin receptors. Physiol Rev 86: 805-847.
20. Evron T, Peterson SM, Urs NM, Bai Y, Rochelle LK, Caron MG, et al., (2014). G protein and beta-arrestin signaling bias at the ghrelin receptor. J Biol Chem 289: 33442-33455.
21. Gautam D, Han SJ, Duttaroy A, Mears D, Hamdan FF, Li JH, et al., (2007). Role of the M3 muscarinic acetylcholine receptor in beta-cell function and glucose homeostasis. Diabetes Obes Metab 9 (Suppl 2): 158-169.
22. Gautam D, Han SJ, Hamdan FF, Jeon J, Li B, Li JH, et al., (2006). A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 3: 449-461.
23. Hanley SC, Austin E, Assouline-Thomas B, Kapeluto J, Blaichman J, Moosavi M, et al., (2010). {beta}-Cell mass dynamics and islet cell plasticity in human type 2 diabetes. Endocrinology 151: 1462-1472.
24. Irwin N, Frizelle P, Montgomery IA, Moffett RC, O'Harte FP, Flatt PR, (2012). Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes. Diabetologia 55: 2747-2758.
25. Irwin N, Frizelle P, O'Harte FP, Flatt PR, (2013). Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal mice. J Endocrinol 216: 53-59.
26. Jin S, Zhuo Y, Guo W, Field J, (2005). p21-Activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. J Biol Chem 280: 24698-24705.
27. Julien S, Laine J, Morisset J, (2004). The rat pancreatic islets: a reliable tool to study islet responses to cholecystokinin receptor occupation. Regul Pept 121: 73-81.
28. Karlsson S, Ahren B, (1992a). CCK-8-stimulated insulin secretion in vivo is mediated by CCKA receptors. Eur J Pharmacol 213: 145-146.
29. Karlsson S, Ahren B, (1992b). Cholecystokinin and the regulation of insulin secretion. Scand J Gastroenterol 27: 161-165.
30. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
31. Kim KS, Abraham DM, Williams B, Violin JD, Mao L, Rockman HA, (2012). beta-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol 303: H1001-H1010.
32. Koliaki C, Doupis J, (2011). Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther 2: 101-121.
33. Kuntz E, Pinget M, Damge P, (2004). Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. JOP 5: 464-475.
34. Lavine JA, Attie AD, (2010a). Gastrointestinal hormones and the regulation of beta-cell mass. Ann N Y Acad Sci 1212: 41-58.
35. Lavine JA, Raess PW, Stapleton DS, Rabaglia ME, Suhonen JI, Schueler KL, et al., (2010b). Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival. Endocrinology 151: 3577-3588.
36. Lawrence M, Shao C, Duan L, McGlynn K, Cobb MH, (2008). The protein kinases ERK1/2 and their roles in pancreatic beta cells. Acta Physiol (Oxf) 192: 11-17.
37. Li B, Wang C, Zhou Z, Zhao J, Pei G, (2013). beta-Arrestin-1 directly interacts with Galphas and regulates its function. FEBS Lett 587: 410-416.
38. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA, (1985). Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75: 1144-1152.
39. Lo CM, Obici S, Dong HH, Haas M, Lou D, Kim DH, et al., (2011). Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice. Diabetes 60: 2000-2007.
40. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
41. Milasta S, Evans NA, Ormiston L, Wilson S, Lefkowitz RJ, Milligan G, (2005). The sustainability of interactions between the orexin-1 receptor and beta-arrestin-2 is defined by a single C-terminal cluster of hydroxy amino acids and modulates the kinetics of ERK MAPK regulation. Biochem J 387 (Pt 3): 573-584.
42. Nelson CD, Perry SJ, Regier DS, Prescott SM, Topham MK, Lefkowitz RJ, (2007). Targeting of diacylglycerol degradation to M1 muscarinic receptors by beta-arrestins. Science 315: 663-666.
43. Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, Rajagopal S, et al., (2011). Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin. Sci Signal 4: ra51.
44. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ,; NC-IUPHAR. (2014) The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
45. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, et al., (2002). Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 298: 834-836.
46. Quoyer J, Longuet C, Broca C, Linck N, Costes S, Varin E, et al., (2010). GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J Biol Chem 285: 1989-2002.
47. Rajagopal S, Rajagopal K, Lefkowitz RJ, (2010). Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9: 373-386.
48. Rehfeld JF, Friis-Hansen L, Goetze JP, Hansen TV, (2007). The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem 7: 1154-1165.
49. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ, (2011). Molecular mechanism of ? Arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52: 179-197.
50. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ, (2012). Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52: 179-197.
51. Ren XR, Reiter E, Ahn S, Kim J, Chen W, Lefkowitz RJ, (2005). Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc Natl Acad Sci U S A 102: 1448-1453.
52. Rorsman P, Braun M, (2012). Regulation of insulin secretion in human pancreatic islets. Annu Rev Physiol 75: 155-179.
53. Shukla AK, Manglik A, Kruse AC, Xiao K, Reis RI, Tseng WC, et al., (2013). Structure of active beta-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature 497: 137-141.
54. Shukla AK, Westfield GH, Xiao K, Reis RI, Huang LY, Tripathi-Shukla P, et al., (2014). Visualization of arrestin recruitment by a G-protein-coupled receptor. Nature 512: 218-222.
55. Shukla AK, Xiao K, Lefkowitz RJ, (2011). Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci 36: 457-469.
56. Silvente-Poirot S, Escrieut C, Wank SA, (1998). Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol Pharmacol 54: 364-371.
57. Simonsson E, Karlsson S, Ahren B, (1996). Involvement of phospholipase A2 and arachidonic acid in cholecystokinin-8-induced insulin secretion in rat islets. Regul Pept 65: 101-107.
58. Simonsson E, Karlsson S, Ahren B, (1998). Ca2+-independent phospholipase A2 contributes to the insulinotropic action of cholecystokinin-8 in rat islets: dissociation from the mechanism of carbachol. Diabetes 47: 1436-1443.
59. Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu JC, Olefsky JM, (2008). Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc Natl Acad Sci U S A 105: 6614-6619.
60. Strachan RT, Sun JP, Rominger DH, Violin JD, Ahn S, Rojas Bie Thomsen A, et al., (2014). Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR). J Biol Chem 289: 14211-14224.
61. Takiguchi S, Takata Y, Funakoshi A, Miyasaka K, Kataoka K, Fujimura Y, et al., (1997). Disrupted cholecystokinin type-A receptor (CCKAR) gene in OLETF rats. Gene 197: 169-175.
62. Tsvetanova NG, von Zastrow M, (2014). Spatial encoding of cyclic AMP signaling specificity by GPCR endocytosis. Nat Chem Biol 10: 1061-1065.
63. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, et al., (2010). Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335: 572-579.
64. Wang HM, Dong JH, Li Q, Hu Q, Ning SL, Zheng W, et al., (2014). A stress response pathway in mice upregulates somatostatin level and transcription in pancreatic delta cells through Gs and beta-arrestin 1. Diabetologia 57: 1899-1910.
65. Whalen EJ, Rajagopal S, Lefkowitz RJ, (2011). Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med 17: 126-139.
66. Wu SV, Yang M, Avedian D, Birnbaumer M, Walsh JH, (1999). Single amino acid substitution of serine82 to asparagine in first intracellular loop of human cholecystokinin (CCK)-B receptor confers full cyclic AMP responses to CCK and gastrin. Mol Pharmacol 55: 795-803.
67. Xiao K, Sun J, Kim J, Rajagopal S, Zhai B, Villen J, et al., (2010). Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107: 15299-15304.
68. Yu X, Duan KL, Shang CF, Yu HG, Zhou Z, (2004). Calcium influx through hyperpolarization-activated cation channels (I(h) channels) contributes to activity-evoked neuronal secretion. Proc Natl Acad Sci U S A 101: 1051-1056.
69. Zawalich WS, Diaz VA, Zawalich KC, (1987). Cholecystokinin-induced alterations in beta-cell sensitivity. Duration, specificity, and involvement of phosphoinositide metabolism. Diabetes 36: 1420-1424.
70. Zhao J, Zhang N, He M, Yang Z, Tong W, Wang Q, et al., (2008). Increased beta-cell apoptosis and impaired insulin signaling pathway contributes to the onset of diabetes in OLETF rats. Cell Physiol Biochem 21: 445-454.